Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (October 2021)
29 slides from Rhythm Biosciences's investor presentation, Oct 25, 2021
Slide 1: Investor Presentation
Investor Presentation 25 October 2021 ASX:RHY A transformative and predictive cancer diagnostics technology company
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 3: Introduction
Introduction Rhythm’s initial product, ColoSTAT® is a simple, low-cost blood test for the early detection of colorectal cancer for global mass-market screening. IP protection secured in all major international jurisdictions. 3
Slide 4: Investment Highlights
Investment Highlights Disruptive and transformative technology Significantly cheaper and easier to administer Globally addressable market Performance better than market standard Manufacturing & Patents secured Initial revenues targeted for 2022 4
Slide 5: Company Overview
Company Overview Capital Structure Share Price Chart ASX Code RHY $7,000,000 $1.80 $6,000,000 $1.60 Share Price (at 22 October 2021) $1.36 $1.40 $5,000,000 $1.20 Shares on Issue 208.8 M $4,000,000 $1.00 Unlisted Options 16.8 M $3,000,000 $0.80 $0.60 Market Capitalisation $275 M $2,000,000 $0.40 $1,0
Slide 6: Colorectal Cancer
Colorectal Cancer COLORECTAL CANCER RISK FACTORS Globally, Colorectal Cancer is currently the 3rd largest cancer by volume with 1.9 million new cases diagnosed annually and 2nd largest cause of cancer related deaths. GLOBAL BURDEN 1.93 million new cases ~940,000 deaths DIAGNOSIS BY STAGE CURRENT TES
Slide 7: Bowel Cancer Treatment Costs Are Increasing
Bowel Cancer Treatment Costs Are Increasing ColoSTAT® is expected to increase participation, leading to earlier detection and avoiding costly treatments “ The National Bowel Cancer $130,000 $120,000 Cost drivers: $110,000 Screening Program could $100,0002 • Private hospital Average treatment cost pe
Slide 8: Current FIT Pathway – Cumbersome & Not Well Adopted
Current FIT Pathway – Cumbersome & Not Well Adopted (<50% compliance globally) FIT Testing Central FIT Sample Pathology Collection lab Process Diagnostic assessment to GP * ➢ Multi step faecal collection, packaging over at least 2 days then posting sample back to a central laboratory. Obligation on
Slide 9: ColoSTAT - Patient Friendly, Increased Compliance
ColoSTAT® - Patient Friendly, Increased Compliance Early detection is the key to survival and reducing the cost of treatment Simple & Routine Patient Journey With ColoSTAT® Government screen / ColoSTAT® has the potential to: GP referral / patient request ✓Significantly increase screening compliance
Slide 10: ColoSTAT - What Is It? How Does It Work?
ColoSTAT® - What Is It? How Does It Work? Unlike the FIT, ColoSTAT® is specific for colorectal cancer – not just blood in faeces. How it works ColoSTAT® Technology Sample Result Low cost assay format which is designed to integrate with existing pathology lab infrastructure. ColoSTAT® Test-Kit Algori
Slide 11: ColoSTAT - Detailed Development History
ColoSTAT® - Detailed Development History Rhythm lists on ColoSTAT® Study 6 Study 7 the ASX prototype test-kit Analytical Clinical trial ISO completed performance completion certification Reagent Global testing complete Two adjunct Program biomarkers manufacturer completed appointed Regulatory valida
Slide 12: Clinical Trial (Study 7) – Performance In A Clinical Setting
Clinical Trial (Study 7) – Performance In A Clinical Setting Trial Study Design End Points Prospective, cross-sectional, multi- Primary: PATIENT RECRUITMENT SUCCESSFULLY COMPLETED centre clinical trial. Performance of ColoSTAT® for detection of CRC relative to Two cohorts: colonoscopy (Sensitivity a
Slide 13: ColoSTAT Performance
ColoSTAT® Performance “83% of unscreened participants prefer a blood test over a faecal test”1 ColoSTAT Sensitivity Performance Comparison • Highly accurate 85% ColoSTAT is 33% more accurate at detecting colorectal cancer than the current market standard Faecal Immunochemical Test (FIT).2 84% 80% 75
Slide 14: Market Opportunity / Addressable Market
Market Opportunity / Addressable Market US$38 billion addressable screening value in priority markets1 Colorectal Cancer Screening Market Population Number of people over 50 years of age eligible for screening Country Screening participation Addressable population United States 63% 94 million $12Bn
Slide 15: Market Likely To Expand Significantly
Market Likely To Expand Significantly ✓ USA Preventative Services Task Force recommends Colorectal Cancer Screening to commence at age 45. Five years younger than it previously recommended, adding circa 20 million patients to the screening population in the USA alone. ✓ Reduction of screening age un
Slide 16: Australia – Growth of CRC in younger age groups
Australia – Growth of CRC in younger age groups 25 – 29 years old 30 – 34 years old 35 – 39 years old 1990 1995 2000 2005 2010 2015 2020 1990 1995 2000 2005 2010 2015 2020 1990 1995 2000 2005 2010 2015 2020 0 0 0 1 1 1 2 2 2 3 3 3 4 4 4 5 5 5 6 6 6 7 7 7 8 8 8 9 9 9 10 10 10 11 11 11 12 12 12 13 13
Slide 17: Unique Opportunity To Add Significant Value
Unique Opportunity To Add Significant Value Seamless alignment across the entire value chain providing broader benefits for the health system Blood test is the Patients preferred testing method. Increased participation in screening. Cheaper testing leads to More lives saved. Reduced Government highe
Slide 18: Market Dynamics
Market Dynamics Lifestyle factors increasing risk profiles Low screening participation rates Late-Stage Bowel Cancer Treatment Costs Are Increased in young onset Colorectal Cancer Increasing >$100k US draft legislation to reduce screening age to Screening reduced during COVID-19 45 years old pandemi
Slide 19: Competitive Landscape – ColoSTAT's Advantage
Competitive Landscape – ColoSTAT®’s Advantage Blood based Epigenomics Novigenix Volition Rx Epi proColon® Colox® Nu.q™ Rhythm ColoSTAT® ~$300 per ~$150 per ~$250 per test test $ TBC test Clinical Genomics Colvera™ ~$400 per test ColoSTAT®’s comparative low cost & simplicity lends itself to global AP
Slide 20: Competitive Landscape – ColoSTAT's Advantage
Competitive Landscape – ColoSTAT®’s Advantage 100% 93% 95% 95% 92% 92% 88% 90% 84% 78% 80% 70% 68% 71% Performance / accuracy 60% of ColoSTAT® versus 50% 40% other more expensive, 30% 20% competitor, blood-based 10% tests 0% Colox Colvera Epi proColon ColoSTAT (Study 6) ColoSTAT (Study 6 + LRF Enhan
Slide 21: Market Entry Strategy
Market Entry Strategy Rhythm’s strategy is underpinned by: ✓ Proven technology; ✓ Build global manufacturing capability; ✓ Secure commercialisation pathway/s; and ✓ Establish partner networks. 21
Slide 22: Market Entry – Platform Technology Expansion
Market Entry Platform Technology Expansion • Confirm Rhythm’s key lead biomarker has global application and is highly expressed in a range of cancers. Building Scale • Shortlist target cancers to focus on. • Complements Rhythm’s simple, low-cost, mass-market cancer diagnostics strategy. • Not expect
Slide 23: Market Entry – Building Scale
Market Entry Platform Technology Expansion • Confirmed test-kit manufacture in house (RHY). • Successful transfer of core technology to Building Scale global manufacturer, Biotem. • Third party manufactured test-kits successfully produced and tested in Study 6 with exceptional results. Priority Mark
Slide 24: Market Entry – Priority Market Entry
Market Entry Platform Technology Expansion • United States / Australia / Europe. • China / Japan / Asia / ROW. • Incorporated a 100% owned USA domiciled Building Scale entity. • Increase business development activity and appropriate partner selection. Priority Market Entry • Target approved Clinical
Slide 25: Market Entry – Regulatory
Market Entry Platform Technology Expansion • Regulatory entry for Europe (CE Mark) and Australia (TGA). • Confirmed approach to submit application for CE Mark in advance of Study 7 completion Building Scale and TGA (Australia) regulatory filing. • CE Mark submission and approval expected in late 202
Slide 26: IP – Patents Filed In All Major Target Markets
IP – Patents Filed In All Major Target Markets Granted Pending ➢ Licensed from CSIRO. United States France India Australia Germany ➢ Worldwide exclusive licence. China (x2) Italy ➢ Patent wholly owned by Rhythm Biosciences Ltd*. Japan Luxembourg ➢ Expires 2031. United Kingdom Netherlands ➢ Methods f
Slide 27: Summary
Summary ✓ Disruptive and transformative technology. ✓ Significantly cheaper and easier to administer. ✓ Globally addressable market. ✓ Performance better than market standard. ✓ Patents secured. ✓ Manufacturing secured. ✓ Initial revenues targeted for late 2022. ✓ Commenced platform technology pipel
Slide 28: Future Value Inflection Points – FY'22
Future Value Inflection Points – FY’22 ✓ CE Mark submission and approval expected in late 2021#. ✓ Progression of TGA (Australia) regulatory application post clinical trial (Study 7) recruitment#. ✓ Development of platform technology opportunities for other cancers. ✓ Advance USA / European / China
Slide 29: Glenn Gilbert CEO, Rhythm Biosciences
Glenn Gilbert CEO, Rhythm Biosciences glenn.gilbert@rhythmbio.com +61 3 8256 2880 www.rhythmbio.com 29
Rhythm Biosciences — Investor Presentation (October 2021) on 6ix